A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Status:
Active, not recruiting
Trial end date:
2024-07-29
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to look whether the type 2 diabetes medicine,
semaglutide, has a positive effect on heart disease. Participants will either get semaglutide
tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance.
Participants must take one tablet with water every morning on an empty stomach and not eat or
drink anything for at least 30 minutes. The study will last for about 3.5-5 years.
Participants will have up to 25 clinic visits and 1 phone call with the study doctor. Women
cannot be in the study if pregnant, breast-feeding or if they plan to become pregnant during
the study period.